GSK 3882347
Alternative Names: GSK-3882347Latest Information Update: 28 Jun 2025
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Anti-infectives; Small molecules; Urinary anti-infective agents
- Mechanism of Action E coli fimH protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Urinary tract infections
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Urinary-tract-infections(In the elderly, In adults) in USA (PO, Capsule)
- 03 Dec 2024 GlaxoSmithKline completes a phase I trial in Urinary tract infections (In adults, In the elderly) in USA (PO) (NCT05138822)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Urinary-tract-infections(Prevention) in United Kingdom (PO, Capsule)